In lung cancer cells, the use of everolimus in combination with GRh2 (Eve-Rh2), by upregulating c-MYC expression, caused the mediated accumulation of tribble homologous protein 3 (TRIB3)/P62+ aggregates that triggered the apoptosis process and inhibited the malignant progression of lung cancer cells, providing a new synergistic therapeutic strategy (18). Here, MYC is linked to lung cancer.